Alkaloid AD SkopjeXMAE:ALK -0.41%84 Interest Coverage is 21.34 as of Mar. 2026, which is 68% below its 10-year median of 65.83. GuruFocus rates XMAE:ALK with a GF Score™ of 84/100 and a GF Value™ of MKD27,166.15 (Modestly Undervalued). Among 684 Drug Manufacturers companies, Alkaloid AD Skopje ranks better than 58.77% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Alkaloid AD Skopje's
Operating Income
for the
three
months ended in Mar. 2026 was MKD840 Mil. Alkaloid AD Skopje's Interest Expense for the
three
months ended in Mar. 2026 was MKD-39 Mil.
Alkaloid AD Skopje's interest coverage for the quarter that ended in Mar. 2026 was 21.34.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Alkaloid AD Skopje's Interest Coverage or its related term are showing as below:
XMAE:ALK'
s Interest Coverage Range Over the Past 10 Years
Min: 20.43 Med: 65.83 Max: 98.39
Current: 20.43
XMAE:ALK's Interest Coverage is ranked better than 58.77% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs XMAE:ALK: 20.43
Alkaloid AD Skopje (XMAE:ALK) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Alkaloid AD Skopje Interest Coverage Related Terms
Alkaloid AD Skopje Interest Coverage Historical Data
* Premium members only.
The historical data trend for Alkaloid AD Skopje's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XMAE:ALK vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alkaloid AD Skopje (XMAE:ALK) has a Interest Coverage of 21.34 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Alkaloid AD Skopje and its competitors. This is 68% below median its historical median of 65.83. Over the past decade, Alkaloid AD Skopje's Interest Coverage has ranged from 20.43 to 98.39. According to the industry distribution chart, Alkaloid AD Skopje ranks #282 out of 684 companies in the Drug Manufacturers industry, placing it in the top 41.2%.
Is Alkaloid AD Skopje's Interest Coverage too high?
Alkaloid AD Skopje's current Interest Coverage of 21.34 is 68% below median its 10-year median of 65.83. Over the past 10 years, this metric has ranged from a low of 20.43 to a high of 98.39. The Drug Manufacturers industry median Interest Coverage is 12.77. Alkaloid AD Skopje's value of 21.34 is 67.2% above this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #282 out of 684 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #282 out of 684 companies for Interest Coverage. This puts Alkaloid AD Skopje in the upper half of its industry. The industry median Interest Coverage is 12.77. Alkaloid AD Skopje's value of 21.34 is 67.2% above this benchmark. Historically, Alkaloid AD Skopje's own Interest Coverage has ranged from 20.43 to 98.39 over the past decade. While the company's 10-year median is 65.83 vs. the industry median of 12.77, Alkaloid AD Skopje has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current Interest Coverage of 21.34 is 67.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Alkaloid AD Skopje and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current Interest Coverage is 21.34, which is 68% below median its own 10-year median of 65.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD27,166.15, compared to a current price of MKD24,200.00 — trading 10.9% below its estimated fair value. The current Interest Coverage is 21.34, which is 68% below median its 10-year median of 65.83 and 67.2% above the Drug Manufacturers industry median of 12.77. Alkaloid AD Skopje's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current Interest Coverage is 21.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD24,200.00 is trading 10.9% below its estimated GF Value™ of MKD27,166.15.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
Interest Coverage: 21.34 (68% below median its 10-year median of 65.83)
GF Value™: MKD27,166.15 vs. price of MKD24,200.00 (10.9% below fair value)
Industry Position: 67.2% above the Drug Manufacturers median (#282 of 684)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
84GF Score
Get the complete analysis for XMAE:ALK
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
